Immunome, Inc.
IMNM
$7.17
-$0.23-3.11%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 9.04M | 10.13M | 10.78M | 12.68M | 14.02M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.04M | 10.13M | 10.78M | 12.68M | 14.02M |
| Cost of Revenue | 129.54M | 91.29M | 57.91M | 34.55M | 23.09M |
| Gross Profit | -120.50M | -81.16M | -47.13M | -21.86M | -9.07M |
| SG&A Expenses | 32.96M | 30.55M | 25.40M | 22.74M | 19.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 162.50M | 121.84M | 83.31M | 57.29M | 42.75M |
| Operating Income | -153.46M | -111.71M | -72.53M | -44.60M | -28.73M |
| Income Before Tax | -292.96M | -305.35M | -262.59M | -232.03M | -106.81M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -292.96 | -305.35 | -262.59 | -232.03 | -106.81 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -292.96M | -305.35M | -262.59M | -232.03M | -106.81M |
| EBIT | -153.46M | -111.71M | -72.53M | -44.60M | -28.73M |
| EBITDA | -151.89M | -110.44M | -71.56M | -44.08M | -28.27M |
| EPS Basic | -5.17 | -6.06 | -5.64 | -5.49 | -3.33 |
| Normalized Basic EPS | -1.47 | -1.12 | -0.92 | -0.89 | -0.90 |
| EPS Diluted | -5.18 | -6.06 | -5.64 | -5.49 | -3.33 |
| Normalized Diluted EPS | -1.47 | -1.12 | -0.92 | -0.89 | -0.90 |
| Average Basic Shares Outstanding | 234.53M | 214.48M | 166.48M | 118.74M | 79.37M |
| Average Diluted Shares Outstanding | 234.53M | 214.48M | 166.48M | 118.74M | 79.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |